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Summary To assess the precise role of IGF1 in benign and malignant breast diseases, we analysed the tissular
localisation, characterised, and quantified specific insulin-like growth factor 1 (IGF1) binding sites in these
heterogenous tissues, using histo-autoradiographic analysis (HAA). The 251I-IGFI binding was performed on
frozen tissue sections and analysed using 'H Ultrofilm autoradiography coupled to computerised image
analysis. Competitive binding experiments using unlabelled IGF1, IGF2 and insulin showed that the tissues
exhibited typical type I IGF binding sites. This specificity was confirmed by the use of alpha IR-3 monoclonal
antibody, as inhibitor of 12I-IGFI binding. IGFI binding sites were detected in 18 human primary breast
cancers, 12 benign breast tumours and two normal breast tissues. Using HAA we found that the human breast
carcinomas studied exhibit a specific and high binding capacity for "'I-IGFI exclusively localised on the
proliferative epithelial component. The "'I-IGFI binding activity of benign breast tumours or normal breast
tissue was significantly lower than in cancerous tissues. There was a significant correlation between IGF1-R
concentrations detected with HAA and those detected with a classical biochemical method. Moreover, HAA
could be useful in further detailing whether a tumour is IGFI-R positive or negative HAA appears to be a
useful method for the detection of growth factor receptors, specially in small biopsy specimens.
Insulin-like growth factor (IGF1), also termed somatomedin
C, is a small polypeptide (M.W. 7400 daltons) whose primary
physiological role is to act on skeletal development via the
endocrine pathway, together with growth hormone (Furna-
letto et al., 1977; Zapf & Froesch, 1986). This factor
stimulates the growth of many cell types (Moses & Pilistine,
1985), including various breast cancer cell lines (Furnaletto &
Di Carlo, 1984; Myal et al., 1984; Huff et al., 1986; Dickson
& Lippman, 1987; Karey & Sirbasku, 1988). IGFI is syn-
thesised in many tissues (D'Ercole et al., 1984; Murphy et al.,
1987; Lund et al., 1986) and immunoreactive IGF1 had been
found in the medium conditioned by breast cancer cell lines
(Baxter et al., 1983; Huff et al., 1986; Minuto et al., 1987).
The recent demonstration of the absence of IGF1 mRNA in
these cells suggests that 'immunoreactive IGF1' represents
either IGF1-related proteins or secreted IGF1 binding pro-
teins (Yee et al., 1989). The presence of IGF1 mRNA in
breast cancers evokes a paracrine role of this factor (Yee et
al., 1989).
The first step in IGFI action is its binding to membrane
receptors (Rosenfeld & Hintz, 1988). IGF1 binding sites have
been characterised by competitive binding and cross-linking
techniques in breast cancer cell lines (Furnaletto & Di Carlo,
1984; Myal et al., 1984; De Leon et al., 1988; Pollak et al.,
1988; Peyrat et al., 1989) as well as in breast cancers (Peyrat
et al., 1988a) or in benign breast diseases (Peyrat et al.,
1988b). We demonstrated that IGF2 was a good competitor
of the binding of "251-IGF1 to IGFI-R whereas insulin com-
peted with a potency lower than 1/100th of IGFI's potency.
Chemical cross-linking experiments revealed that the appar-
ent molecular weight of the binding site was 130,000 daltons
(Peyrat et al., 1988a). Therefore, the IGF1 specific binding
sites share a close structural homology with insulin receptor
and correspond to the previously described type I IGF recep-
tors (IGF1-R) in normal tissues. It has recently been shown
that the mitogenic effect of IGF2 on breast cancer epithelial
cell lines (Karey & Sirbasku, 1988; Yee et al., 1988) could be
mediated, at least partially, by IGFI-R (Osborne et al., 1989;
Cullen et al., 1990).
Several authors have demonstrated that most breast
cancers contain IGF1-R (Peyrat et al., 1988a; Pollack et al.,
1987; Pekonen, 1988; Foekens et al., 1989). In our study, the
presence of IGF1-R is associated to a better prognosis
(Bonneterre et al., 1990). Conversely, IGF1-R are found less
frequently and at lower concentrations in benign breast
diseases (Peyrat et al., 1988b). These results suggest that
IGF1-R could be a marker of the proliferative epithelial
component inside the tumour. However, all of these studies
had been performed using membrane preparations, which do
not allow the precise localisation of binding sites in a
heterogeneous tissue such as breast cancer. The development
of techniques based on autoradiography, and specially of
quantitative densitometry analysis, has allowed the localisa-
tion of receptors, and particularly of IGFI-R, in different
heterogeneous tissues such as the brain (Israel et al., 1984;
Bohannon et al., 1986), the adrenal gland (Shigematsu et al.,
1989) and the ovary (Monget et al., 1989).
We have used this technique to specify the localisation and
to quantify high affinity IGFI-R in benign and malignant
human breast tumours.
Patients, materials and methods
Tumour collection
Tumour specimens were obtained from patients undergoing
surgery for primary breast cancer or benign breast tumour in
the Centre Oscar Lambret (Lille, France). At the time of
collection fat was removed and samples were divided into
three parts. One portion was submitted to histological
analysis, while the others were immediately frozen in liquid
nitrogen until histo-autoradiographic analysis (HAA) and
biochemical receptor determinations.
Our series was composed of 13 ductular, two lobular, one
colloid, one ductular lobular and one comedo invasive
carcinoma, of six dystrophy, five fibroadenomas, and one
phyllod tumour. Two normal breasts was also analysed.
IGF1 labelling
Human synthetic IGF1 was purchased from Eli Lilly Com-
pany (Indianapolis, USA). A modification of the method of
Hunter and Greenwood, using a low concentration of chlor-
amine T, was employed to iodinate IGF1 (Peyrat et al.,
1988a). Specific activity, as calculated by isotope recovery,
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was 2,000 Ci mmole '. The quality of the labelled IGFl was
checked after each iodination using a standard laboratory
preparation of BT-20 breast cancer cell-line membrane recep-
tors. The tracer was considered usable when 400tLg of the
usual protein membrane preparation specifically bound 10%
of the iodinated IGF1 (Peyrat et al., 1988a).
Quantitative IGFJ-R autoradiography
Frozen sections (7pm) were processed as previously des-
cribed (Haour et al., 1987). Briefly the slide-mounted sections
were preincubated for 10min at 20°C in 'Tri-HCl' buffer
(Tris 50 mM; pH 7.4) containing 2 mM CaCl2 and 5 mM KCI.
The sections were then washed twice with 'Tri-HCl' buffer.
Incubation was carried out at 20°C for 30 min in Tris-HCI
(120mM, pH 7.4) containing 0.1% BSA and 0.45nM 12511
IGF1 (106cpmml-1) according to the experimental condi-
tions described by Bohanon et al. (1986) and Shigematsu et
al. (1989). Non-specific binding was determined in the
presence of 5 x10-7 M IGF1. In some cases, the competition
was achieved with alpha IR3 monoclonal antibody (pur-
chased from Clinisciences, France) that specifically blocks
breast cancer IGF1-R (Pollak et al., 1988; Rohlik et al.,
1987; Arteaga & Osborne, 1989). After pre-incubation of
cryostat sections in the presence or absence of10 .g ml-' of
alpha IR-3 in Tris-HCl buffer during one hour at room
temperature, the 251I-IGFI was added. Following the incuba-
tions, the sections were washed three times for 10 min in
ice-cold Tris-HCl buffer (50 mM), dried, and exposed for 7
days to Amersham autoradiographic films (3H-hyperfilm).
The films were processed and the relative density of'251-IGF1
binding sites was quantified by computerised densitometry
using an image analyser (RAG 200, BIOCOM, Les Ulis,
France). It was related to the concentration of radioactivity
as based on a comparison with standard curves generated by
processing sets of Amersham '251-microscale; the results were
expressed in femtomoles of ligand bound per milligram of
proteins (Israel et al., 1984). Normal human liver was used as
negative control as it is an abundant producer of IGFl
binding protein but expresses very little type I IGF receptor.
Biochemical IGFJ receptor assay
The frozen tissue was weighed and then pulverised
(Spex-Bioblock France). The tissues were homogenised in
20 mM Tris HCI, 3 mM EDTA, 1 mM dithiothreitol, 0.01%
azide, pH 7.6. The homogenate was centrifuged at 800g for
10 min. and the supernatant was ultracentrifuged at
105,000g for 60 min. The supernatant (cytosol) was removed
and the pellet ('microsomal' fraction) was resuspended in
25 mm Tris-HCl, 10mM MgCl2, 0.1 mM phenylmethylsul-
fonyl fluoride, pH 7.6 (Tris-MgCl2 buffer). The protein con-
centration was determined by the method of Lowry et al.
(1951) applied either directly in the cytosol fraction, or after
extraction from the membranes (with NaOH 1 N) in the
microsomal fraction.
The binding test was described previously (Peyrat et al.,
1988a): 400 gLg of membrane proteins were incubated for 5 h
at 4°C with approximately 200,000 cpm of iodinated IGF1 in
the presence or absence of an excess of unlabelled IGF1. The
final incubation volume was adjusted to 0.5 ml with Tris-
MgCl2 buffer containing 0.1% bovine serum albumin (frac-
tion V, ref. A3912, Sigma Chemical Company, St. Louis,
MD, USA). Bound receptors were separated by a 3,000g,
30min. centrifugation. In our experimental conditions, the
iodinated ligand was not saturating and the 251I-IGFI specific
binding was expressed as a percentage of total radioactivity.
Results
Autoradiographic analysis and characterisation ofIGFI-R
The binding specificities of '25I-IGFl to the breast cancer
sections are analysed in several tumours and shown in Figure
la. `25-IGFI binding to the receptor was inhibited by
unlabelled IGF1 (10-"to I0-7 M) in a concentration depen-
dent manner. The non-specific binding obtained in the
presence of an excess of IGF1 (5x 10- M), represented 25%
of '25I-IGF1 total binding. IGF2, in the same concentrations
(10-9 to 10-7M), also displaced 251I-IGF1 binding. In our
experimental conditions, insulin competed for IGF1 receptor,
but was much less efficient than IGF1. When the non-specific
binding was determined using alpha IR-3, the mouse mono-
clonal antibody that is highly specific for IGFI receptor
(Rohlik et al., 1987; Pollak et al., 1988; Arteaga & Osborne,
1989), 72% of total '25I-IGFl binding was inhibited by alpha
IR3 (Figure la). The data in Figure lb show the saturation
curves of the '25I-IGFl binding as a function of the labelled
IGFl concentration in two breast carcinoma cases. As
illustrated, the high binding was associated with a higher
maximum binding capacity (Bmax, fmoles mg-' of protein)
without a modification of affinity (a Kd approximate value of
1.5 nM).
Cellular localisation and quantification of'25I-IGFJ specific
binding
Breast tumours are heterogeneous tissues composed of
epithelial cells, connective tissue, fibroblasts and adipocytes.
The autoradiographic analysis made possible the character-
isation and mapping of1251I-IGF1 specific binding in several
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Figure 1 a,Inhibitory curves of '25I-IGF1 binding by unlabelled
IGF1, IGF2 and insulin. The breast cancer sections were
incubated at 20°C for 30 min in the presence of 0.45 nM '25I-IGFI
(106cpmmlh') with or without the indicated concentration of
IGF1 or IGF2 or insulin as indicated in Materials and methods.
Each point represent the mean of two independent determina-
tions for an individual carcinoma. Two different carcinoma were
analysed. 0 IGFI; 0 IGF2; A insulin; 0 aIR3. b, Saturation
curve of 1251-IGFI binding in two individual breast cancers (no. I
0; no. 2 0). The tissue sections were incubated with various
concentrations of '251-IGFI and the non-specific binding deter-
mined in the presence of an excess of unlabelled IGF1 (5 x
10-7M).
.w250 H. JAMMES et al.
biopsies. Figure 2 shows typical examples of histo-auto-
radiograms obtained by '251-IGFl binding on ductular breast
cancer sections. The densitometric autoradiographic analysis
of the whole section of the tumours allowed the quanti-
fication of global total binding (44.8 fmolesmg-' protein,
Figure 2a) and non-specific binding (12.2 fmolesmg-' pro-
tein, Figure 2b). The specific binding was 32.6 fmolesmg-'
protein. However, the staining was not uniform. Some areas
contained a high density of IGF1-R and others a very low
density. It is possible to quantify the total binding and the
non-specific binding for each area and to determine the
corresponding tissue component. The area which showed a
a
high density of specific binding (total binding: 65 fmoles
mg-' protein; non-specific binding: 15 fmolesmg-' protein)
exclusively contained proliferative epithelial cells as shown in
Figure 2c. The areas where IGF1 specific binding was very
low or undetectable (total binding: 26 fmolesmg-' protein,
specific binding: 7 fmolesmg-' protein) were associated to
connective tissue. A very high non-specific IGFI binding was
observed in the central area corresponding to residual necro-
sis in a mammary duct.
Figure 3 shows autoradiographic images of '25I-IGFI in
the adjacent mastosis tissue of the same ductular breast
cancer. The specific binding in the whole section was 0.4
b
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Figure 2 Colour-coded computerised autoradiographic images of '25I-IGFI binding in ductular breast carcinoma no. 1. a, shows
total binding obtained by incubation with 0.45 nm '25I-IGFI and b, non specific binding defined in the presence of an excess of
unlabelled IGF1 (5 x 10-7M). After incubation, the tissue sections were exposed to 3H Ultrofilm for 7 days. The relative binding
density is indicated by the colour spectrum; red corresponds to the highest binding, and blue to the lowest binding (see colour
scale). c, shows the histologic analysis of the same section (after autoradiography, slides were fixed and and stained with
hematoxylin and eosin; the magnification, = 20). EC: epithelial cells; CT: connective tissue; G: mammary duct; NR: necrosis residues.HISTO-AUTORADIOGRAPHIC ANALYSIS OF IGFI RECEPTOR IN BREAST CANCER 251
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Figure 3 Autoradiographic images of '25I-IGF1 binding in adjacent mastosis tissue of ductular breast cancer. a, shows total
binding and b, non specific binding.
fmoles mg-' protein (Total binding: 7.7 fmoles mg-' protein;
non-specific binding: 7.3 fmolesmg-I protein) and the stain-
ing was uniform. In this tissue, the histologic analysis
revealed an absence of proliferative epithelial cells.
Thirty tumours and two normal breast tissues were
analysed for the presence of IGF1-R. The comparison of the
biochemical and autoradiographic analysis of IGFI specific
binding was performed for all biopsies tumours except the
colloid one for which the membrane preparation was not
possible (HAA value: 30 fmoles mg-' of proteins). To estab-
lish this correlation, the results of some detection in non-
breast tissue were also included. The pairs of values observed
by the biochemical and autoradiographic analysis were
respectively: for two samples of tumoral endometrium (8.27/
63.4; 2.83/212), for the ovary tumour (2.41/74.6), for the
normal liver (0.94/9.36) and for the tumoral liver (3.96/84.2).
Figure 4 shows the correlation between the results obtained,
demonstrating a highly significant positive correlation
between the two methods. Using the biochemical method we
considered that tumours were negative when the specific
binding was lower than 1% (Peyrat et al., 1988b). Using this
criterion, six tumours were found to be negative, with the
more sensitive autoradiographic method, IGFl specific bind-
ing was detectable in the same tumours.
The specific IGFI binding, in the breast cancers, was
particularly high and had a wide range in the breast cancers.
The median concentration was 30 fmoles mg-' of proteins
(50% of values were between 19 and 60 fmoles mg-' of
proteins, range 1.9-1!14). It was significantly higher (p <
0.001) than the median concentration in benign disease (0.7
fmoles mg-' of proteins, 50% ofvalues were between 0.5 and
0.9 fmoles mg-' of proteins, range 0-8.6). In the two normal
breast tissues studied, the IGFI specific binding was detect-
able but low (0.8 and 6.2 fmoles mg' of proteins). In the
same incubation conditions, the normal human liver, which
expresses few IGF1 receptors and was used as negative cont-
rol, exhibited a '251-IGFI specific binding of 9.36 fmoles
mg-' of proteins.
In six cases, IGF1-R were detected both in the breast
carcinoma tissue and in the adjacent benign breast disease
tissue, demonstrating much lower concentrations in the latter
(Figure 5). Interestingly, in most breast carcinomas (15/18) it
was possible to detect areas with a significantly high density
of labelling. Conversely, in benign breast diseases or normal
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Figure 4 Correlation between biochemical analysis (Receptor-
Ligand-Assay, RLA) and histo-autoradiographic analysis (HAA)
of IGFI specific binding for 30 biopsied tumours (13 ductular,
two lobular, one ducto-lobular carcinoma; six distrophic diseases,
five fibroadenoma, one phyllod tumour), two normal breast and
several tumoral tissues (endometrium, ovary, liver). The values of
specific binding (Bs) determined from microsomial fractions were
expressed as % of total radioactivity and the values determined
by autoradiographic analysis expressed in fmolesmg-' of pro-
teins. (Spearman rank correlation: r = 0.76). 0 Breast cancer; -
Benign breast disease; 0 Normal breast; A Other tumoral tis-
sues.
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Figure 5 Relation between the '25I-IGFI specific binding deter-
mined in breast carcinoma and adjacent benign disease tissue. In
six individual cases, biopsies were obtained from breast cancer
tissue (four ductal, one lobular and one invasive comedo car-
cinoma) and from adjacent disease-tissue. 0 Adjacent benign
disease tissue; * Breast cancer tissue.
breast (11/12) the IGF1-R labelling was diffuse and there
were no areas with a higher IGFI-R concentration.
Discussion
The specificity of the '25I-IGFl binding determined by HAA,
in breast cancer sections, was similar to our previous findings
using membrane preparations (Peyrat et al., 1988a). IGF1
was the most potent ligand (versus IGF2 and insulin) to
inhibit the 251I-IGFl binding. The relative affinity of receptor
to IGFI, IGF2 and insulin exhibited typical type I binding
site (IGFl>IGF2>>>insulin). Several groups have demon-
strated that breast cancer cells secreted IGF1 binding pro-
teins into their conditioned media (Yee et al., 1989; De Leon
et al., 1989; Yee et al., 1991). The IGF binding proteins were
characterised by their ability to bind radiolabelled IGFI or
IGF2 and not insulin. The results of our competition binding
assays suggest the absence of IGF binding proteins on breast
slide preparations. The tissue frozen sections were not fixed
and it is likely that soluble binding proteins were eliminated
during the incubations. This was confirmed by the low level
of 251I-IGF1 binding in normal human liver which is very
rich in binding proteins. The use of alpha IR-3 monoclonal
antibody clearly reinforced the fact that 251I-IGFI binding
detected by autoradiographic analysis on breast cancer sec-
tons, was specific of type I IGF receptor.
We found a significant correlation between IGF1-R histo-
autoradiographic and biochemical quantifications, demons-
trating that it is possible to utilise HAA to assay IGF1-R.
Moreover, HAA allows the tissular localisation of IGFI-R in
very heterogenous tissue such as breast tumours. IGF1
specific binding is limited to the areas of breast tumours that
represent target tissue for IGF1. In fact, HAA demonstrates
that specific binding sites are localised on the epithelial com-
ponent; whereas the stromal tissue as well as the duct lumina
contained only unspecifically bound IGFl. Most of the
human breast cancers studied exhibited strong IGF1 specific
binding. In benign breast diseases, low levels of specific
binding were detected either in distrophic diseases, which
contain few epithelial cells or in fibroadenomas, which are
epithelium-rich tissues. These results suggest that pro-
liferating epithelial cells were labelled by 25I-IGF1; it would
be interesting to analyse specific '25I-IGFI binding in
epithelial atypical hyperplasia. The concept of the importance
of IGF1-R as proliferative marker can be applicable for
other tissues like human lung cancers (Shigematsu et al.,
1990), neoplastic endometrium (Talavera et al., 1990) and
colon cancer cells (Guo et al., 1990). We have some results
indicating high levels of IGF1-R in neoplastic endometrium,
ovaries and liver carcinoma (Figure 4). HAA also appears to
have a potential interest in the analysis of the ontogeny of
IGFI binding in relation to the evolution of mastopathy to
carcinoma, and also in the receptor quantification in tumours
with a limited amount of tissue.
HAA allows precise analysis of the significance of low
IGF1-R levels in the tumours. In fact, the low levels could
correspond to two contrasting situations: either a diffuse
labelling of the tissue (as in benign breast diseases) or a
heterogeneous labelling with limited areas containing rela-
tively high IGF1-R concentrations (as is the case for the
colloid tumour). It can be proposed that in the latter situa-
tion, the tumours would present clusters of epithelial cells
containing an appreciable quantity of IGF1 receptors and
would develop under IGF1 stimulation. In all cancers con-
sidered as negative (<1%) by biochemistry, using HAA we
detected very low levels of specific binding (3 fmoles mg-'
protein). A detailed analysis of the sections demonstrated
that, in these tumours, there were no areas with high IGF1-R
concentration. In contrast, we detected by biochemical
analysis five breast cancers with low IGF1-R levels (between
1 to 2%); HAA allowed the discrimination of two categories
of tumours in this group. In two individual cases, the labell-
ing was diffuse (with 1.8 and 20 fmoles mg-' protein of
specific '251I-IGFI binding, respectively) and these tumours
could be considered as negative. In other tumours, HAA
demonstrated a heterogeneity of specific labelling with
clusters of IGF1-R rich cells (with 44.7, 46.5 and 100 fmoles
mg-' protein of specific binding in cell clusters respectively)
and the tumours were positive. Clearly, the HAA was potent
technique to reveal the presence of IGF1-R in tumours and
improve the classification of these tumours as IGF1-R nega-
tive or positive. We have demonstrated that a poor prognosis
is associated with negative, biochemically detected, IGFI-R
(Bonneterre et al., 1990). HAA could be useful for a better
selection of IGF1-R negative tumours.
In conclusion, HAA should be highly useful for examining
tumour heterogeneity with respect to IGFl-responsiveness.
IGF1 is an important growth factor in breast cancer and
IGFI-R is a good marker of epithelial proliferation.
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